William Blair Has Pessimistic Outlook of Certara Q3 Earnings

Certara, Inc. (NASDAQ:CERT - Free Report) - Stock analysts at William Blair dropped their Q3 2025 earnings per share estimates for Certara in a research note issued on Monday, April 14th. William Blair analyst M. Smock now expects that the company will post earnings of $0.07 per share for the quarter, down from their prior estimate of $0.09. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Certara's current full-year earnings is $0.28 per share. William Blair also issued estimates for Certara's Q3 2026 earnings at $0.09 EPS and Q4 2026 earnings at $0.08 EPS.

Several other brokerages have also recently issued reports on CERT. Barclays dropped their target price on shares of Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. TD Cowen assumed coverage on Certara in a report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective on the stock. Stephens reaffirmed an "overweight" rating and set a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. KeyCorp upped their price target on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday. Finally, Robert W. Baird lifted their target price on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Certara presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.17.

Certara Stock Performance

Shares of NASDAQ CERT traded up $0.62 during midday trading on Tuesday, hitting $14.15. The company's stock had a trading volume of 2,114,112 shares, compared to its average volume of 1,188,632. The firm has a market cap of $2.28 billion, a P/E ratio of -70.75, a P/E/G ratio of 9.29 and a beta of 1.64. The firm's fifty day moving average price is $11.62 and its 200-day moving average price is $11.46. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara has a 1-year low of $8.64 and a 1-year high of $17.94.

Institutional Trading of Certara

Several hedge funds and other institutional investors have recently made changes to their positions in the company. ArrowMark Colorado Holdings LLC raised its holdings in Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock worth $66,171,000 after purchasing an additional 3,861,674 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in Certara by 864.0% in the fourth quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock valued at $40,253,000 after buying an additional 3,387,590 shares during the period. Mackenzie Financial Corp bought a new stake in Certara during the fourth quarter valued at $17,852,000. Brown Brothers Harriman & Co. grew its holdings in Certara by 63.8% during the 4th quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock worth $40,668,000 after acquiring an additional 1,487,998 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Certara by 169.0% in the 4th quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock valued at $21,248,000 after purchasing an additional 1,253,385 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.